All In Biotech

Drug Trial Radar · NCT07920939

Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes

A Phase III, Multicenter, Randomized, Open-Label, Parallel-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 450 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2027

Study completion Jul 2028

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy and safety of SHR-3167 versus Insulin glargine in insulin-naive type 2 diabetes inadequately controlled on non-insulin anti-diabetic drugs. The hypothesis is that SHR-3167 is non-inferior to insulin glargine in the change of HbA1c from baseline after 26 weeks of treatment.

Conditions

  • Type 2 Diabetes

Interventions

  • SHR-3167 InjectionDrug

    SHR-3167 Injection

  • Insulin glargine (IGlar)Drug

    Insulin glargine (IGlar)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c from baseline to week 26 (non-inferiority test)Time frame: baseline to week 26

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • First Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.